脑转移瘤立体定向放疗后生存≥3年的分级预后模型(GPM ≥ 3Ys)
研究基于接受伽玛刀立体定向放射外科(SRS)治疗的脑转移瘤患者,在测试队列3237例中筛选与生存≥3年相关的临床因素并建立GPM ≥ 3Ys评分系统,在验证队列3317例中验证。两个队列中四个分级间的中位生存期差异均有统计学意义(p < 0.0001),且95%CI无重叠,提示该模型有助于筛选可接受更积极治疗的患者。
要点
- GPM ≥ 3Ys依据肿瘤数目、性别、KPS、原发癌种、原发灶控制及颅外转移六项因素评分。
- 评分总和分为0-9、10-19、20-29、30-36四个等级,各级生存差异显著。
- 测试与验证队列中生存≥3年者分别占8.9%与10.5%。
核心结论
- GPM ≥ 3Ys系统虽为回顾性研究,但被证明对医生为预期可长期生存的患者选择更积极的治疗方式非常有用。
研究设计与样本
- 回顾性研究:测试队列为第二作者实施的伽玛刀SRS治疗的3237例患者,验证队列为第三作者独立实施的3317例患者。
- 以生存≥3年为目标变量,在测试队列中分析临床因素与生存时间的关系建立模型,并在验证队列中检验效度。
主要发现
- 测试队列中289例(8.9%)、验证队列中348例(10.5%)生存3年或以上。
- 测试队列分析显示五个因素与生存≥3年高度相关,据此赋分并建立模型。
- 测试队列与验证队列中四个分级间中位生存期均差异显著(p < 0.0001),95%CI无重叠。
关键数值与推荐
- 肿瘤数目1/2-4/≥5分别计6/1/0分;女性/男性计5/0分;KPS ≥80%/<80%计5/0分。
- 原发癌为乳腺/肺/消化道/其他分别计1/0/3/0分;原发癌已控制/未控制计8/0分;存在/不存在颅外转移计5/0分。
- 按总分分为0-9、10-19、20-29、30-36四个等级。
临床怎么用
- 可依据该评分对SRS治疗的脑转移瘤患者分层,辅助判断哪些患者可能长期生存并适合更积极的治疗。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: As more cancer patients with brain metastases (BMs) are surviving longer due to recent advancements in various treatment modalities, we developed a grading system for stereotactic radiosurgery (SRS)-treated BM patients with long survival. This is a Graded Prognostic Model for Patients Surviving 3 Years or More (GPM ≥ 3Ys). MATERIALS AND METHODS: First, using clinical factor-survival time analysis of 3237 patients in whom gamma knife (GK) SRS was performed by the second author (test cohort), we developed the GPM ≥ 3Ys based on survival ≥3 years as the objective variable. The validity of this model was then tested using another series of 3317 patients independently undergoing GK SRS performed by the third author (verification cohort). Number of patients surviving 3 years or more were 289 (8.9%) and 348 (10.5%), respectively. RESULTS: Using the test series, among various pre-SRS clinical factors, noted below, five were shown to be highly correlated with survival of ≥3 years. Therefore, we assigned scores for these five factors, i.e., "tumor numbers 1/2-4/≥5 (score; 6/1/0)", "female/male (5/0)", "KPS ≥80%/<80% (5/0)", "primary cancers of breast/lung/gastrointestinal tract/other (score; 1/0/3/0)", "controlled primary cancer/not (8/0)" and "existing extra-cerebral metastases/not (5/0). Patients were categorized into four grades according to the sum of scores, i.e., 0-9, 10-19, 20-29 and 30-36. Post-SRS mean survival times (MSTs) differed significantly (p < 0.0001) with no overlapping of 95% confidence intervals (CIs) among the four grades. Also, in the verification series, MSTs differed significantly (p < 0.0001) with no overlapping of 95% CI among the four grades of the GPM ≥ 3Ys system. CONCLUSION: Although this was a retrospective study, the GPM ≥ 3Ys system was shown to be very useful to physicians selecting among more aggressive treatment modalities for patients in whom longer survival can be expected.
引用
- Sato Y, Yamamoto M, Serizawa T, et al. A graded prognostic model for patients surviving 3 years or more (GPM ≥ 3Ys) after stereotactic radiosurgery for brain metastasis. Radiother Oncol. 2020. PMID: 33249092. doi:10.1016/j.radonc.2020.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。